Home 
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.3, p.190–195,2021
Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.3, p.190–195,2021
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.122, No.3, p.190–195,2021 |
||
| Title: Congenital disorders of glycosylation – an umbrella term for rapidly expanding group of rare genetic metabolic disorders – importance of physical investigation | ||
| Author: D. E. Lekka, J. Brucknerova, A. Salingova, C. Sebova, M. Ostrozlikova, J. Ziburova, M. Nemcovic, S. Sestak, J. Bellova, Z. Pakanova, B. Sivakova, M. Skoknova, V. Bzduch, J. Mucha, P. Barath, I. Brucknerova | ||
| Abstract: AIM: Congenital disorders of glycosylation (CDG) belong to an expanding group of rare genetic metabolic disorders caused by defects in the complex chemical enzymatic process of glycosylation. The study is aimed at presenting a case report of a premature dysmorphic newborn, clinical presentation of the condition, the way it was diagnosed and treated, as well as its comparison with the known cases. RESULTS: The result of glycan analysis supports the assumption of a supposed glycosylation disorder and also specifies a specific subtype: CDG-1, subtype ALG12-CDG (Ig). CONCLUSION: CDG have an extremely wide clinical spectrum and should be considered in any child with unexplained developmental delay, failure to thrive, seizures, and abnormalities in liver enzymes, coagulation and immunologic factors. The treatment of most forms of CDG depends upon numerous factors such as specific symptoms present, severity of the disorder, age and overall health of the patients and tolerance to certain medications or procedures. For these reasons, the treatment is specific for every individual. It is based on the symptoms and requires a coordination of efforts of a team of specialists (Tab. 4, Fig. 3, Ref. 19). |
||
| Keywords: newborn, congenital disorders of glycosylation, antithrombin III | ||
| Published online: 12-Feb-2021 | ||
| Year: 2021, Volume: 122, Issue: 3 | Page From: 190, Page To: 195 | |
| doi:10.4149/BLL_2021_030 |
||
|
|
 download file |
|